615 related articles for article (PubMed ID: 28722790)
21. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
[TBL] [Abstract][Full Text] [Related]
22. Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
Porter DP; Toma J; Tan Y; Solberg O; Cai S; Kulkarni R; Andreatta K; Lie Y; Chuck SK; Palella F; Miller MD; White KL
HIV Clin Trials; 2016 Feb; 17(1):29-37. PubMed ID: 26899540
[TBL] [Abstract][Full Text] [Related]
23. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
van Lunzen J; Antinori A; Cohen CJ; Arribas JR; Wohl DA; Rieger A; Rachlis A; Bloch M; Segal-Maurer S; Garner W; Porter D; Bosse M; Piontkowsky D; Chuck SK; De-Oertel S
AIDS; 2016 Jan; 30(2):251-9. PubMed ID: 26684822
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Pérez-Hernández IA; Martínez MA; Mayorga ML; González-Domenech CM; Omar M; Olalla J; Romero A; Romero JM; Pérez-Camacho I; Hernández-Quero J; Santos J
Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):815-9. PubMed ID: 26879392
[TBL] [Abstract][Full Text] [Related]
25. Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection.
Mu Y; Pham M; Podany AT; Cory TJ
Expert Opin Pharmacother; 2020 Mar; 21(4):389-397. PubMed ID: 31957507
[No Abstract] [Full Text] [Related]
26. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
[TBL] [Abstract][Full Text] [Related]
27. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
[TBL] [Abstract][Full Text] [Related]
28. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
Campo R; DeJesus E; Bredeek UF; Henry K; Khanlou H; Logue K; Brinson C; Benson P; Dau L; Wang H; White K; Flaherty J; Fralich T; Guyer B; Piontkowsky D
Clin Infect Dis; 2013 Jun; 56(11):1637-45. PubMed ID: 23362296
[TBL] [Abstract][Full Text] [Related]
29. Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study.
Falcon-Neyra L; Palladino C; Navarro Gómez ML; Soler-Palacín P; González-Tomé MI; De Ory SJ; Frick MA; Fortuny C; Noguera-Julian A; Moreno EB; Santos JL; Olbrich P; López-Cortés LF; Briz V; Neth O;
Medicine (Baltimore); 2016 Jun; 95(24):e3842. PubMed ID: 27310962
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.
Gianotti N; Poli A; Nozza S; Spagnuolo V; Tambussi G; Bossolasco S; Cinque P; Maillard M; Cernuschi M; Galli L; Lazzarin A; Castagna A
J Int AIDS Soc; 2015; 18(1):20037. PubMed ID: 26232000
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV.
Taramasso L; Lo Caputo S; Magnasco L; Briano F; Poliseno M; Bruno SR; Ferrara S; Pincino R; Sarteschi G; Beltramini S; Sasso E; Mora S; Giacomini M; Bassetti M; Di Biagio A
AIDS Res Hum Retroviruses; 2022 Jun; 38(6):472-479. PubMed ID: 35172617
[TBL] [Abstract][Full Text] [Related]
32. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
Pinnetti C; Di Giambenedetto S; Maggiolo F; Lorenzini P; Fabbiani M; Tommasi C; Latini A; Ammassari A; Loiacono L; Sterrantino G; Bellagamba R; Boumis E; Antinori A; Zaccarelli M
J Int AIDS Soc; 2014; 17(4 Suppl 3):19812. PubMed ID: 25397556
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study.
Gazaignes S; Resche-Rigon M; Gatey C; Yang C; Denis B; Fonsart J; Desseaux K; Guionie M; Rozenbaum W; Delaugerre C; Molina JM
Antivir Ther; 2016; 21(4):329-36. PubMed ID: 26566057
[TBL] [Abstract][Full Text] [Related]
34. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Orkin C; DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Vandercam B; de Wet J; Rockstroh J; Lazzarin A; Rijnders B; Podzamczer D; Thalme A; Stoeckle M; Porter D; Liu HC; Cheng A; Quirk E; SenGupta D; Cao H
Lancet HIV; 2017 May; 4(5):e195-e204. PubMed ID: 28259777
[TBL] [Abstract][Full Text] [Related]
35. Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.
Amiel C; Schneider V; Guessant S; Hamidi M; Kherallah K; Lebrette MG; Chas J; Lependeven C; Pialoux G
J Antimicrob Chemother; 2014 Dec; 69(12):3335-9. PubMed ID: 25114163
[TBL] [Abstract][Full Text] [Related]
36. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
Allavena C; Dailly E; Reliquet V; Bonnet B; Pineau S; André-Garnier E; Boutoille D; Bouquié R; Raveleau A; Bouchez S; Billaud E; Raffi F
J Antimicrob Chemother; 2014 Oct; 69(10):2804-8. PubMed ID: 24907142
[TBL] [Abstract][Full Text] [Related]
37. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
[TBL] [Abstract][Full Text] [Related]
39. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione SA; Cherian SM; Özdener AE
J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
[TBL] [Abstract][Full Text] [Related]
40. Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
Gianotti N; Poli A; Nozza S; Galli L; Galizzi N; Ripa M; Merli M; Carbone A; Spagnuolo V; Lazzarin A; Castagna A
BMC Infect Dis; 2017 Nov; 17(1):723. PubMed ID: 29145807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
